



PRESS RELEASE

Amoéba, one of the major players in French biotech, renews for the third time a financing line of up to 23 million euros with Nice & Green to support its development.

Chassieu (France), December 21, 2020 – 5.45 pm – AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a new contract for the issue of bonds convertible into shares (OCAPI) and a subordination agreement between Amoéba, Nice & Green SA and the European Investment Bank (EIB).

This new 24-month financing line is intended to give Amoéba the means to finance its key activities, in particular the development of its biocontrol product, and to restructure its debt.

Valérie FILIATRE, Deputy Managing Director of Amoéba, positively comments this second financial agreement:

"The relationship of mutual trust that we have developed with Nice & Green over the last 2 years has naturally led us to set up this new line of financing, unprecedented in the history of Amoéba. This operation will enable us to develop our biocontrol application worldwide on field crops, to continue the examination of our regulatory files and to restructure the company's debt while strengthening its equity".

This new financing will be effectively launched at the end of the convertible bond issue plan currently in place between Amoéba and Nice & Green, the last tranche of which is due to be issued in March 2021.

FOR FURTHER INFORMATION:

Adela KORSELT

CFO - Nice & Green SA

™ TEL: +41 22 361 37 95

E-MAIL: <u>akorselt@nicengreen.ch</u>

About Amoéba

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products. Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

About Nice & Green SA

Nice & Green SA is an independent Swiss Proprietary Equity Investment and Alternative Financing company who helps micro and small-sized listed companies to secure funding needed for their growth. Nice & Green is owned and managed by two principals and capitalizes on establishing long term financial partnership with the companies it assists. More information on www.nicengreen.ch.